KLP Kapitalforvaltning’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$27.4M Buy
317,222
+11,300
+4% +$1M 0.08% 206
2026
Q2
$27.7M Buy
305,922
+2,700
+0.9% +$226K 0.09% 213
2026
Q1
$24.3M Buy
303,222
+7,900
+3% +$651K 0.1% 203
2025
Q4
$25.2M Sell
295,322
-10,900
-4% -$895K 0.1% 190
2025
Q3
$23.8M Buy
306,222
+14,600
+5% +$1.14M 0.09% 206
2025
Q2
$22.8M Buy
291,622
+77,400
+36% +$5.77M 0.1% 201
2025
Q1
$15.5M Sell
214,222
-7,800
-4% -$558K 0.08% 264
2024
Q4
$16.4M Buy
+222,022
New +$15.5M 0.08% 251

Other funds holding EW

KLP Kapitalforvaltning's EW Position: Q3 2026 in Review

KLP Kapitalforvaltning increased its Edwards Lifesciences (EW) stake by 3.7% in Q3 2026, buying an estimated $1M and bringing the position to 317,222 shares worth $27.4M. The position accounts for 0.08% of the portfolio, ranked #206.

KLP Kapitalforvaltning first reported a position in EW in Q4 2024 and has held it in 8 quarters since. The position peaked at $27.7M in Q2 2026. 1,345 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • KLP Kapitalforvaltning held 317,222 shares of Edwards Lifesciences worth $27.4M as of Q3 2026.
  • KLP Kapitalforvaltning bought 11,300 Edwards Lifesciences shares in Q3 2026, an estimated $1M.
  • Edwards Lifesciences made up 0.08% of KLP Kapitalforvaltning's portfolio in Q3 2026, its #206 holding.
  • KLP Kapitalforvaltning first reported a position in Edwards Lifesciences in Q4 2024 and has held it in 8 quarters since.
  • KLP Kapitalforvaltning's Edwards Lifesciences position peaked at $27.7M in Q2 2026.
  • 1,345 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q3 2026, filed 10 Nov 2026.